Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Blood|December 4, 2020
Rapid single-molecule digital detection of protein biomarkers for continuous monitoring of systemic immune disordersYujing Song, Erin Sandford, Yuzi Tian, et al.Critical Care Medicine|July 14, 2021
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter StudyCristina Gutierrez, Anne Rain T Brown, Heather P May, et al.JACC. Cardiooncology|January 11, 2024
Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk FactorsAlexi Vasbinder, Christopher W Hoeger, Tonimarie Catalan, et al.Molecular Therapy. Advances|May 20, 2026
Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trialDaniel Nunez, Jenell R Volkov, Courtney Little, et al.The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.Blood Advances|November 4, 2020
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomaMarcelo C Pasquini, Zhen-Huan Hu, Kevin Curran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.Journal of the American Heart Association|December 29, 2023
Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk ScoreAlexi Vasbinder, Tonimarie Catalan, Elizabeth Anderson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.Pageof 4